Alexander A. Navarini, Petr Hrúz, Christoph T. Berger, Tie Zheng Hou, Charlotte Schwab, Annemarie Gabrysch, Rebecca Higgins, Natalie Frede, Barbara-Christina Padberg Sgier, Olle Kämpe, Anne‐Valérie Burgener, Florian Marquardsen, Fabian Baldin, Marc B. Bigler, Anne Kistner, Annaïse Jauch, Olivier Bignucolo, B. Meyer, Fabian Meienberg, Matthias Mehling, Lukas T. Jeker, Ingmar Heijnen, Thomas Daikeler, Jan‐Olaf Gebbers, Bodo Grimbacher, David M. Sansom, Raphael Jeker, Christoph Hess, Mike Recher,
In 2007, a 39-year-old white male (unique patient identifier [UPI]: CTLA-4_AAA.II.1) presented with chronic, noninfectious diarrhea. The patient's history was noticeable for adrenal insufficiency diagnosed in 1991. In 2013, his diarrhea worsened, resulting in weight loss of more than 20 kg and severe dehydration. Prednisolone (1 mg/kg of body weight given for several weeks) was entirely ineffective. Macroscopic enterocolitis was seen, corresponding histologically to extensive infiltration with CD3+ ...
Tópico(s): Blood groups and transfusion
2016 - Elsevier BV | Journal of Allergy and Clinical Immunology
Gerhard Schmitt, Michael Salzmann, Fabian Jeker,
... werden.07.03.2006 | Gerhard Schmitt, Michael Salzmann & Fabian Jeker (Zürich)
Tópico(s): Education Methods and Technologies
2006 - Forum Neue Medien in der Lehre Austria | Zeitschrift für Hochschulentwicklung
... 2004Crossref PubMed Scopus (212) Google Scholar, 33Zhou X. Jeker L.T. Fife B.T. Zhu S. Anderson ...
Tópico(s): Extracellular vesicles in disease
2013 - Elsevier BV | Journal of Allergy and Clinical Immunology
Maximilian Merz, Anca‐Maria Albici, Bastian von Tresckow, Kristin Rathje, Roland Fenk, Tobias A.W. Holderried, Fabian Müller, Natalia Tovar, Aina Oliver‐Caldés, Vladan Vučinić, Soraya Kharboutli, Ben‐Niklas Bärmann, Francis Ayuk, Uwe Platzbecker, Friedrich Stölzel, Nathalie Schub, Friederike Schmitz, David Fandrei, Patrick Born, Cyrus Khandanpour, Christine Hanoun, Keven Hörster, Marcel Teichert, Barbara Jeker, Michèle J. Hoffmann, Nicolaus Kröger, Carlos Fernández de Larrea, Thomas Pabst, Nico Gagelmann,
Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Leveraging an international multicenter RRMM cohort, we compared the outcome of ide-cel (n = 162) versus cilta-cel (n = 42). Co-primary efficacy endpoints of the study were overall response rate (ORR) and progression-free survival (PFS). Co-primary safety endpoints were the incidence of cytokine release syndrome (CRS) ...
Tópico(s): Protein Degradation and Inhibitors
2025 - Wolters Kluwer | HemaSphere
Nico Gagelmann, Friedrich Stölzel, Roland Fenk, Tobias A.W. Holderried, Fabian Mueller, Natalia Tovar, Aina Oliver‐Caldés, Kristin Rathje, Vladan Vučinić, Soraya Kharboutli, Ben‐Niklas Bärmann, Francis Ayuk, Uwe Platzbecker, Anca Maria Albici, Natalie Schub, Friederike Schmitz, Cyrus Khandanpour, Marcel Teichert, Barbara Jeker, Nicolaus Kroeger, Bastian von Tresckow, Carlos Fernández de Larrea, Thomas Pabst, Maximilian Merz,
Tópico(s): Protein Degradation and Inhibitors
2024 - Elsevier BV | Blood
Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel, Tobias A.W. Holderried, Roland Fenk, Fabian Müller, Natalia Tovar, Aina Oliver‐Caldés, Kristin Rathje, James A. Davis, David Fandrei, Vladan Vučinić, Soraya Kharboutli, Ben‐Niklas Baermann, Francis Ayuk, Uwe Platzbecker, Anca‐Maria Albici, Nathalie Schub, Friederike Schmitz, Leyla Shune, Jack Khouri, Faiz Anwer, Shahzad Raza, Joseph P. McGuirk, Zahra Mahmoudjafari, Kimberly Green, Cyrus Khandanpour, Marcel Teichert, Barbara Jeker, Michèle J. Hoffmann, Nicolaus Kröger, Bastian von Tresckow, Carlos Fernández de Larrea, Thomas Pabst, Al‐Ola Abdallah, Nico Gagelmann,
Abstract Despite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following relapse after BCMA-directed CAR T-cell therapy. Here, we analyzed outcomes of post-CAR T-cell therapy relapse and impact of different salvage strategies in an international cohort of 139 patients ( n = 130 ide-cel, n = 9 cilta-cel), receiving talquetamab ( n = 28), ...
Tópico(s): Multiple Myeloma Research and Treatments
2024 - Springer Nature | Blood Cancer Journal